Toxicity and feasibility of vincristine,etoposide, and carboplatin alternating with vincristine,doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala |
| |
| Authors: | Zachary Graff Veronica Giron Kristen Miller Dyna Pixtun Amanda Alejos Sandra Luna-Fineman |
| |
| Institution: | 1. Children's Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;2. Unidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala;3. Children's Hospital Colorado, School of Medicine, University of Colorado Anschutz Campus, Aurora, Colorado, USA |
| |
| Abstract: | Retinoblastoma is highly curable, with event-free survival (EFS) of greater than 95% in high-income countries. However, in lower middle-income countries, outcomes of EFS are 30%–60% due to delayed diagnosis and lack of resources resulting in extra-ocular disease. We report the toxicity profile and outcomes of intensified therapy for advanced retinoblastoma: vincristine, etoposide, carboplatin (VEC) alternating with vincristine, doxorubicin, and cyclophosphamide (VDoCx) in Guatemala. Compared to VEC alone, similar rates of neutropenia, anemia, and thrombocytopenia were seen, with no toxic deaths. Although survival was not a primary objective, a modest survival benefit supports further investigation of VEC+VDoCx for advanced retinoblastoma. |
| |
| Keywords: | advanced stage global health retinoblastoma therapy |
|
|
